Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age15-50
SponsorCombined Military Hospital Abbottabad

About this trial

Comparative efficacy of topical 1% clotrimazole vs oral itraconazole in the treatment of pityriasis versicolor -Randomized control trial

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age (15-50 years)

Both genders

Sufferers of Pityriasis versicolor ( Determined by scale , erythema and pruritus)

Disqualifiers

Pt with history of antifungals in last one month

Pt on immunosuppressants or steroid therapy

Pregnant and lactating women

Pt with chronic medical conditions ( Diabetes and hypertension)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Topical 1 % clotrimazole twice daily 2 weeks

    Drug

    Topical 1% clotrimazole twice daily for 2 weeks

  • Oral itraconazole 200mg daily for 5 days

    Drug

    Oral itraconazole 200mg daily for 5 days

Treatment groups

86 Participants
are divided into 2 treatment groups
Group A: 1% ClotrimazoleExperimental treatment 1 intervention
Group B: ItraconazoleExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Percentile efficacy of topical versus oral antifungal in the treatment of pityriasis versicolor

Data analysis will be performed using SPSS version 20. The quantitative variable (age, BMI and duration of PV) will be presented as mean ± standard deviation (SD) or median interquartile range (IQR) after checking normality of data by using Shapiro-Wilk test. Frequency and percentages will be used for categorical variables (gender, severity of PV, area of residence, level of education and efficacy). Efficacy will be compared between groups using Chi-square or Fisher exact test. Efficacy will be stratified by age, gender, BMI, duration of PV and severity of PV to deal with effect modifiers. Post-stratification chi-square test or Fischer exact test will be used as test of significance. A p-value of ≤ 0.05 will be considered statistically significant.

Time frame
3 months

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: